These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
    Author: Nagao S, Sato K, Osada Y.
    Journal: Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442.
    Abstract:
    Macrophage (MA) activation by recombinant murine interferon-gamma (rMuIFN-gamma) and a synthetic muramyl dipeptide derivative, N alpha-(N-acetylmuramyl-L-alanyl-D-isoglutaminyl)-N epsilon-stearoyl-L-lysine [MDP-Lys(L18)], was examined. The cytostatic activity of MA that had been primed with rMuIFN-gamma against Lewis lung adenocarcinoma cells was augmented extensively by exposure to MDP-Lys(L18) for a minimum of 15 min, though such treatment in the reverse sequence interfered with the effects of rMuIFN-gamma on MA. The binding assays revealed that rMuIFN-gamma bound to MA with an apparent dissociation constant (Kd) of 0.93 X 10(-9) M (16,000 binding molecules/cell), while MDP-Lys(L18) bound nonspecifically and was endocytosed by MA at 37 degrees. The amount of MDP-Lys(L18) bound to the rMuIFN-gamma-primed MA was significantly greater than that bound to the MA without rMuIFN-gamma priming. A small increase in the amount of MDP-Lys(L18) associated with MA was also observed at 4 degrees, but the amount was one order of magnitude less than that at 37 degrees. The binding of rMuIFN-gamma to MA was significantly suppressed by priming with MDP-Lys(L18). These results indicate that the binding of rMuIFN-gamma in preference to MDP-Lys(L18) to MA is of great importance in the mechanisms of MA activation.
    [Abstract] [Full Text] [Related] [New Search]